The tyrosine kinase Src is activated in a large number of human malignancies and plays significant roles in the development of cancers. Activation of Src in human cancers employs a variety of mechanisms mainly including covalent modification, allosteric regulation, gene mutation. Covalent modifications of Src mainly include phosphorylation and oxidization. Tyr530, Tyr419, Thr34, Thr46, Ser72, Tyr138 and Tyr213 are phosphorylation sites of Src, among which Tyr530 and Tyr419 are the most important ones. Allosteric regulations of Src involve its regulatory Src homology 3 (SH3) or SH2 domains, which interacts with allosteric regulators, such as FAK, PR, ER, AR, P130Cas, PDGF, PDGFR, EGFR, HER2, IGF-1R, FGFR-1, c-Met, p13, Nef and Sin.
Ponatinib
From $132
PP-121
From $90
PP1
From $95
PP2
From $90
Saracatinib
From $123
SM1-71
$100
Src Inhibitor 1
From $115
Src Inhibitor 3
$100
SU6656
From $85
TG 100572
From $125
TG 100572 Hydrochloride
From $150
TG 100801
From $125
TG 100801 Hydrochloride
From $125
WH-4-023
From $90
XL228
From $100
β-Hydroxyisovalerylshikonin
From $515